BFPW
VRTX icon

BOK Financial Private Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

BOK Financial Private Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$493K Sell
1,103
-159
-13% -$74.1K 0.03% 121
2025
Q4 		$572K Sell
1,262
-17
-1% -$7.33K 0.04% 118
2025
Q3 		$501K Buy
1,279
+21
+2% +$8.78K 0.03% 125
2025
Q2 		$560K Sell
1,258
-531
-30% -$245K 0.04% 117
2025
Q1 		$867K Sell
1,789
-194
-10% -$90.4K 0.07% 98
2024
Q4 		$799K Sell
1,983
-374
-16% -$173K 0.06% 106
2024
Q3 		$1.1M Sell
2,357
-236
-9% -$113K 0.08% 99
2024
Q2 		$1.22M Sell
2,593
-22
-0.8% -$9.55K 0.09% 98
2024
Q1 		$1.09M Sell
2,615
-476
-15% -$201K 0.08% 99
2023
Q4 		$1.26M Sell
3,091
-325
-10% -$120K 0.1% 92
2023
Q3 		$1.19M Sell
3,416
-806
-19% -$282K 0.1% 93
2023
Q2 		$1.49M Sell
4,222
-767
-15% -$258K 0.12% 88
2023
Q1 		$1.57M Buy
4,989
+604
+14% +$181K 0.13% 91
2022
Q4 		$1.27M Buy
+4,385
New +$1.34M 0.11% 92
2022
Q2 		– Sell
-1,405
Closed -$367K – 446
2022
Q1 		$367K Buy
1,405
+355
+34% +$84.3K 0.03% 205
2021
Q4 		$231K Buy
+1,050
New +$204K 0.02% 268

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BOK Financial Private Wealth's VRTX Position: Q1 2026 in Review

BOK Financial Private Wealth reduced its Vertex Pharmaceuticals (VRTX) stake by 13% in Q1 2026, selling an estimated $74.1K and leaving 1,103 shares worth $493K. The position accounts for 0.03% of the portfolio, ranked #121.

BOK Financial Private Wealth first reported a position in VRTX in Q4 2021 and has held it in 16 quarters since. The position peaked at $1.57M in Q1 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • BOK Financial Private Wealth held 1,103 shares of Vertex Pharmaceuticals worth $493K as of Q1 2026.
  • BOK Financial Private Wealth sold 159 Vertex Pharmaceuticals shares in Q1 2026, an estimated $74.1K.
  • Vertex Pharmaceuticals made up 0.03% of BOK Financial Private Wealth's portfolio in Q1 2026, its #121 holding.
  • BOK Financial Private Wealth first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 16 quarters since.
  • BOK Financial Private Wealth's Vertex Pharmaceuticals position peaked at $1.57M in Q1 2023.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on BOK Financial Private Wealth's 13F filing for Q1 2026, filed 12 May 2026.